Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Administration of oxaliplatin to a pregnant woman with rectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY Gensheimer, M., Jones, C. A., Graves, C. R., Merchant, N. B., Lockhart, A. C. 2009; 63 (2): 371-373

Abstract

The platinum agent oxaliplatin could be useful in treatment of cancer in pregnant women, but it is fetotoxic in rats and its effect on the human fetus is unknown.Oxaliplatin was administered to a 25-year-old pregnant woman with metastatic rectal cancer from 20 to 30 weeks gestational age as part of the mFOLFOX-6 regimen.The patient gave birth to a healthy girl at 33 weeks gestational age. At follow-up, the 3-year-old child had achieved all appropriate growth and developmental milestones.Oxaliplatin is a component of several modern chemotherapy regimens. This report demonstrates the administration of oxaliplatin in the second and third trimesters of pregnancy without apparent fetal harm.

View details for DOI 10.1007/s00280-008-0731-9

View details for Web of Science ID 000261286800020

View details for PubMedID 18357450